These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 14556007

  • 21. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.
    Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG.
    Nat Cell Biol; 2000 Jul; 2(7):423-7. PubMed ID: 10878807
    [Abstract] [Full Text] [Related]

  • 22. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
    Baba M, Hirai S, Yamada-Okabe H, Hamada K, Tabuchi H, Kobayashi K, Kondo K, Yoshida M, Yamashita A, Kishida T, Nakaigawa N, Nagashima Y, Kubota Y, Yao M, Ohno S.
    Oncogene; 2003 May 08; 22(18):2728-38. PubMed ID: 12743597
    [Abstract] [Full Text] [Related]

  • 23. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.
    Pugh CW, Ratcliffe PJ.
    Semin Cancer Biol; 2003 Feb 08; 13(1):83-9. PubMed ID: 12507560
    [Abstract] [Full Text] [Related]

  • 24. Hypoxia-mediated Na-K-ATPase degradation requires von Hippel Lindau protein.
    Zhou G, Dada LA, Chandel NS, Iwai K, Lecuona E, Ciechanover A, Sznajder JI.
    FASEB J; 2008 May 08; 22(5):1335-42. PubMed ID: 18073334
    [Abstract] [Full Text] [Related]

  • 25. Decreased growth of Vhl-/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27.
    Mack FA, Patel JH, Biju MP, Haase VH, Simon MC.
    Mol Cell Biol; 2005 Jun 08; 25(11):4565-78. PubMed ID: 15899860
    [Abstract] [Full Text] [Related]

  • 26. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.
    Ivanova AV, Ivanov SV, Danilkovitch-Miagkova A, Lerman MI.
    J Biol Chem; 2001 May 04; 276(18):15306-15. PubMed ID: 11278694
    [Abstract] [Full Text] [Related]

  • 27. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression.
    Pioli PA, Rigby WF.
    J Biol Chem; 2001 Oct 26; 276(43):40346-52. PubMed ID: 11517223
    [Abstract] [Full Text] [Related]

  • 28. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL.
    Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, Maxwell PH, Ratcliffe PJ, Stuart DI, Jones EY.
    Nature; 2002 Jun 27; 417(6892):975-8. PubMed ID: 12050673
    [Abstract] [Full Text] [Related]

  • 29. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex.
    Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, Ohh M.
    J Biol Chem; 2003 Mar 28; 278(13):11032-40. PubMed ID: 12538644
    [Abstract] [Full Text] [Related]

  • 30. von Hippel-Lindau tumor suppressor: not only HIF's executioner.
    Czyzyk-Krzeska MF, Meller J.
    Trends Mol Med; 2004 Apr 28; 10(4):146-9. PubMed ID: 15162797
    [Abstract] [Full Text] [Related]

  • 31. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development.
    Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG, Ohh M.
    Mol Cell Biol; 2004 Apr 28; 24(8):3251-61. PubMed ID: 15060148
    [Abstract] [Full Text] [Related]

  • 32. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.
    An J, Rettig MB.
    Mol Cell Biol; 2005 Sep 28; 25(17):7546-56. PubMed ID: 16107702
    [Abstract] [Full Text] [Related]

  • 33. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [Abstract] [Full Text] [Related]

  • 34. pVHL mediates K63-linked ubiquitination of nCLU.
    Xue J, Lv DD, Jiao S, Zhao W, Li X, Sun H, Yan B, Fan L, Hu RG, Fang J.
    PLoS One; 2012 Sep 15; 7(4):e35848. PubMed ID: 22532874
    [Abstract] [Full Text] [Related]

  • 35. Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain.
    Lolkema MP, Gervais ML, Snijckers CM, Hill RP, Giles RH, Voest EE, Ohh M.
    J Biol Chem; 2005 Jun 10; 280(23):22205-11. PubMed ID: 15824109
    [Abstract] [Full Text] [Related]

  • 36. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage.
    Roe JS, Kim HR, Hwang IY, Cho EJ, Youn HD.
    Oncogene; 2011 Jul 14; 30(28):3127-38. PubMed ID: 21358672
    [Abstract] [Full Text] [Related]

  • 37. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.
    Nyhan MJ, O'Sullivan GC, McKenna SL.
    Biochem Soc Trans; 2008 Jun 14; 36(Pt 3):472-8. PubMed ID: 18481984
    [Abstract] [Full Text] [Related]

  • 38. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.
    Zimmer M, Doucette D, Siddiqui N, Iliopoulos O.
    Mol Cancer Res; 2004 Feb 14; 2(2):89-95. PubMed ID: 14985465
    [Abstract] [Full Text] [Related]

  • 39. Tid-1 interacts with the von Hippel-Lindau protein and modulates angiogenesis by destabilization of HIF-1alpha.
    Bae MK, Jeong JW, Kim SH, Kim SY, Kang HJ, Kim DM, Bae SK, Yun I, Trentin GA, Rozakis-Adcock M, Kim KW.
    Cancer Res; 2005 Apr 01; 65(7):2520-5. PubMed ID: 15805242
    [Abstract] [Full Text] [Related]

  • 40. Molecular targets from VHL studies into the oxygen-sensing pathway.
    Maynard MA, Ohh M.
    Curr Cancer Drug Targets; 2005 Aug 01; 5(5):345-56. PubMed ID: 16101382
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.